Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Parallel, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hypercholesterolemia at High or Moderately High Risk for Coronary Heart Disease

Trial Profile

A Multicenter, Randomized, Double-Blind, Parallel, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hypercholesterolemia at High or Moderately High Risk for Coronary Heart Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Atorvastatin
  • Indications Hypercholesterolaemia; Hyperlipidaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms VYTELD
  • Sponsors Merck & Co
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 19 Jan 2013 Planned number of patients changed from 1293 to 1361 as reported by European Clinical Trials Database.
    • 18 Oct 2012 Planned number of patients changed from 1275 to 1293.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top